Medscape Identification of High-Risk Dyslipidemias From Screening to Effect of Treatment Faculty Wei Chieh Jack Tan, MD Adjunct Assistant Professor Deputy Head Senior Consultant Department of Cardiology Director, Coronary Care Unit National Heart Centre Singapore Singapore, SingaporeHigh-Risk Dyslipidemia in Asia * Dyslipidemia is an important risk factor for CVD in Asia * Dyslipidemia remains underdiagnosed and undertreated in Asians * FHis an underrecognized disorder * Statins are the first-line therapy * A significant proportion of patients don’t achieve the LDL target or do not tolerate the treatment * PCSK9 inhibitors demonstrated consistent and highly effective reduction of LDL-C in patients taking maximally tolerated statinsCV Death, MI, Stroke, UA, or Coronary Revascularization in the FOURIER trial * Relative reduction of LDL-C: 59% (95% Cl: 58, 60) * Absolute reduction of LDL-C: 56 mg/dL (95% Cl: 55, 57) 1.45 mmol/L (95% Cl: 1.42, 1.47) <0.5 0.5to13 131018 18t026 226 0.76 0.85 0.94 0.97 reen (0.64, 0.90) (0.76, 0.96) (0.82, 1.09) (0.86, 1.09) Giugliano RP, et al. Lancet. 2017. [Epub ahead of print.]